Featured Post from Augusta University

Was it Dora that finally discovered the key to diversity at the box office?

Sep 10, 2019

2 min

A.B. Osborne

If you have young kids – or have at least been around them over the past 20 years – you’ll know Dora the Explorer, the always polite adventurer who takes excited young viewers on a trek through South America while educating them at the same time.


The star of Nickelodeon has her own theme song, branded toys and clothes, along with a cast of characters who have also become household names.

 

The show has been a success on the small screen, but the cross-over to live action proved to be gold at theaters, too, and the movie has already grossed more than $80 million at the worldwide box office.


Dora and the Lost City of Gold is a smashing success, and for more reasons than just name recognition.


Dora, played by Isabela Moner, is the strong female lead of a cast that is almost entirely made up of actors from Latin backgrounds. The film continues to show the success of gender and racial diversity in Hollywood.


The move toward increased diversity also includes the LGBTQ community and people with disabilities. 


“There is a major push for representation in both of these communities and we're still reaching new milestones there every day,” said A.B. Osborne, assistant professor of animation at Augusta University. "Steven Universe and the recent She-Ra reboot have been major breakthroughs for authentic and positive LGBTQ representation. Steven Universe, for example, had the first same-sex marriage proposal and wedding for a kid's animated series. Rebecca Sugar, the creator, had to work very hard to get Cartoon Network to agree to that moment."


Osborne adds, “Another milestone that means a lot to a good friend of mine who has Asperger's syndrome is the creation of Symmetra from Overwatch. She was the first autistic playable videogame character.


It’s not all positive, however. Disney recently announced that Halle Bailey would be playing Ariel in its remake of The Little Mermaid. The backlash was loud, but Disney has not wavered, stating the young African American actress is perfect for the role.


Diversity and inclusion in film and society is always an important albeit sensitive topic – and if you are covering stories about diversity, let our experts help.


Osborne is an expert in the field of animation, working in everything from classic cartoons to technical and medical animation. He is available to speak with media regarding this topic – simply click on his icon to arrange an interview.

Connect with:
A.B. Osborne

A.B. Osborne

Assistant Professor of Animation in Pamplin College of Arts, Humanities, and Social Sciences; Department of Art and Design

A.B. Osborne is an expert in the the field of animation working in everything from classic cartoons to technical and medical animation.

Motion GraphicsTechnical and Medical VisualizationAnimation3D ModelingVirtual and Augmented Reality
Powered by

You might also like...

Check out some other posts from Augusta University

2 min

From Libraries to Heart Health: Marlo Vernon Takes Cardiovascular Care Into Rural Georgia

Marlo Vernon, PhD, associate professor in the Department of Health Management, Economics, and Policy at Augusta University’s School of Public Health, is leading a creative public health initiative designed to improve cardiovascular monitoring in rural Georgia. Through the university’s Rural Obese At-Risk initiative, Vernon and her team are placing blood pressure monitors in local libraries, allowing residents to check them out just like books. The effort addresses a critical access gap in rural communities where preventive health tools are often limited or difficult to obtain. Vernon’s work focuses on the realities facing communities in the South’s so-called Stroke Belt, where overlapping health conditions significantly elevate cardiovascular risk. View her profile “There are significant chronic disease risk factors in this so-called Stroke Belt. We’ve got high obesity rates. We have family history. We have high rates of diabetes and kidney disease and they all kind of feed into each other to really create this cardiovascular health need in our communities. And women, in general, are just at a higher risk for this,” said Marlo Vernon, PhD. Beyond equipment access, Vernon’s research also examines how people understand and manage their health when traditional care options are limited. The library-based model helps normalize blood pressure monitoring while reducing barriers such as travel distance, cost, and limited clinic availability. It also creates opportunities to study how community-based solutions can improve awareness, engagement, and long-term cardiovascular outcomes. For journalists covering rural health, women’s health, chronic disease prevention, or innovative public-health strategies, Vernon offers grounded, real-world insight into how trusted community spaces can play a vital role in addressing persistent health disparities. A full article on this topic is available below.  To arrange an interview with Dr. Vernon simply click on her iconnow  to set up a time to talk today.

2 min

Why Insomnia May Hold the Key to Treating Depression, According to MCG Research

William Vaughn McCall, MD, professor emeritus in the Department of Psychiatry and Health Behavior at the Medical College of Georgia at Augusta University, is leading a new multi-year clinical trial aimed at addressing insomnia and depression together — two conditions that frequently occur side by side. The Assessing Improvements in Mood and Sleep (AIMS) Trial, funded by the National Institutes of Health, is exploring whether treating sleep problems through psychotherapy can also reduce lingering symptoms of depression, particularly in older adults. McCall has served as professor and Case Distinguished Chairman of the Department of Psychiatry and Health Behavior at Augusta University since 2012. His research interests include depression, electroconvulsive therapy, quality of life, insomnia, and suicide. His research has been continuously funded by the National Institute of Mental Health since 1995, and he is the author of more than 400 publications, including more than 180 peer-reviewed journal articles. View his profile McCall’s work builds on decades of research examining how disrupted sleep contributes to mood disorders. While previous studies often focused on medication-based approaches, this trial takes a different direction by testing non-pharmacological therapies that target insomnia itself. The research team, which includes collaborators from multiple universities, is evaluating whether improving sleep quality can meaningfully lower depression symptoms for patients who remain symptomatic despite antidepressant treatment. “Ultimately, the hope is to find other avenues to reduce the risk for depression and depression symptoms,” McCall says. The trial is currently recruiting adults aged 55 and older who are experiencing both insomnia and depression, with options for both in-person and remote participation. For journalists covering mental health, aging, sleep science, or emerging clinical research, McCall is a key expert offering informed perspective on how sleep-focused interventions could reshape the future of depression treatment. The full article 'New MCG trial targets insomnia and depression symptoms' is available below: And if you're interested in talking with William Vaughn McCall, MD, simply click on his icon now  to arrange a time for an interview today.

3 min

AU scientists advance understanding of Nobel-winning immunology research

The 2025 Nobel Prize in Physiology or Medicine recognized the discovery of regulatory T cells, which are immune cells that maintain tolerance and prevent autoimmunity. At Augusta University, scientists have built upon that foundational work, uncovering how these cells function, fail and evolve across diseases like cancer and atherosclerosis. Regulatory T cells, or Tregs, are essential for controlling immune responses and preventing the body from attacking its own tissues. Early discoveries by Shimon Sakaguchi, MD, PhD, who identified the CD25 marker and later the transcription factor FoxP3, revealed how Tregs suppress immune activation. Sakaguchi, a distinguished professor at Osaka University in Japan, shared the Nobel Prize with Mary E. Brunkow, PhD, Princeton University, and Fred Ramsdell, PhD, University of California, Los Angeles. Sakaguchi once shared lab space with Nicholas Gascoigne, PhD, now a professor at AU’s Immunology Center of Georgia, where he studies T-cell signaling and differentiation — a connection that ties the global history of Treg research to the university’s ongoing expertise. Gascoigne’s research continues to illuminate how Tregs differentiate and signal, critical steps in ensuring immune tolerance to self. “Drs. Sakaguchi, Brunkow and Ramsdell have made enormous contributions to our understanding of how immunological tolerance works, so this prize is very well deserved,” Gascoigne said. “I was happy I could help Drs. Shimon and Noriko Sakaguchi when they needed lab space back in the early ‘90s. They were wonderful to work with.” At Augusta University, David Munn, MD, co-director of the Pediatric Immunotherapy Program of the Medical College of Georgia at Augusta University, made seminal discoveries showing that Tregs are not always stable. Munn’s team demonstrated that these cells could lose their suppressive identity and become “exTregs,” adopting pro-inflammatory characteristics under certain conditions. Munn also uncovered an entirely distinct tolerance mechanism through indoleamine 2,3-dioxygenase, a pathway independent of FoxP3 that regulates immune balance through tryptophan metabolism. “In particular, the work of Shimon Sakaguchi and Fred Ramsdell was profoundly influential on our early work, as we were just starting out to explore how the immune system is regulated in pediatric cancers,” Munn said. “The work of these Nobel laureates helped transform the scientific understanding of how the immune system responds — or fails to respond — in the setting of tumors.” Catherine “Lynn” Hedrick, PhD, co-director of the Immunology Center of Georgia, further expanded this understanding by showing that Tregs can convert into follicular helper T cells, offering new insight into how immune regulation can shift toward antibody production in chronic inflammatory diseases such as atherosclerosis. “Understanding how regulatory T cells can shift identities helps explain why the immune system sometimes loses balance in chronic disease,” Hedrick said. “By tracing how Tregs convert into other helper cells, we’re uncovering new therapeutic targets to restore immune harmony in conditions like atherosclerosis.” Building on these advances, Klaus Ley, MD, co-director of IMMCG, and his team have investigated how exTregs contribute to cardiovascular inflammation, identifying them in human tissues and clarifying their role in atherosclerosis. His lab also recently discovered human exTregs, providing the first direct evidence of these cells in people. Two postdoctoral fellows in Ley’s lab, Qingkang Lyu, PhD, and Smriti Parashar, PhD, continue this work, exploring how regulatory and ex-regulatory T cells influence chronic disease progression. Additionally, Dimitrios Moskofidis, MD, PhD, a professor based in the Georgia Cancer Center, contributed key early insights into immune tolerance and memory, defining how effector T cells persist or are deleted following infection. “Together, these discoveries place Augusta University and the Immunology Center of Georgia at the forefront of modern immunology, connecting molecular mechanisms of tolerance to real-world diseases and therapies,” Ley said. To connect with any of the experts or researchers in this article - simply contact AU's External Communications Team mediarelations@augusta.edu to arrange an interview today.

View all posts
Powered by